Relapsed and refractory pediatric acute myeloid leukemia: Current and emerging treatments

Jennifer G. Davila, Emily Slotkin, Thomas Renaud

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Survival rates for children with acute myeloid leukemia (AML) exceed 60 % when modern, intensified chemotherapeutic regimens and enhanced supportive care measures are employed. Despite well-recognized improvements in outcomes, primary refractory or relapsed pediatric AML yields significant morbidity and mortality, and improved understanding of this obstinate population along with refined treatment protocols are urgently needed. Although a significant number of patients with refractory or relapsed disease will achieve remission, long-term survival rates remain poor, and efforts to identify therapies which will improve OS are under continuous investigation. The current fundamental goal of such investigation is the achievement of as complete a remission as possible without dose-limiting toxicities, and the progression to hematopoietic stem cell transplantation thereafter. In this review the scope of the problem of relapsed and refractory AML as well as current and emerging chemotherapy options will be discussed.

Original languageEnglish (US)
Pages (from-to)151-168
Number of pages18
JournalPediatric Drugs
Volume16
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Pediatrics
Survival Rate
Hematopoietic Stem Cell Transplantation
Clinical Protocols
Therapeutics
Morbidity
Drug Therapy
Mortality
Population

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

Relapsed and refractory pediatric acute myeloid leukemia : Current and emerging treatments. / Davila, Jennifer G.; Slotkin, Emily; Renaud, Thomas.

In: Pediatric Drugs, Vol. 16, No. 2, 2014, p. 151-168.

Research output: Contribution to journalArticle

@article{665f9644b71c48d9a82dd3e443714af3,
title = "Relapsed and refractory pediatric acute myeloid leukemia: Current and emerging treatments",
abstract = "Survival rates for children with acute myeloid leukemia (AML) exceed 60 {\%} when modern, intensified chemotherapeutic regimens and enhanced supportive care measures are employed. Despite well-recognized improvements in outcomes, primary refractory or relapsed pediatric AML yields significant morbidity and mortality, and improved understanding of this obstinate population along with refined treatment protocols are urgently needed. Although a significant number of patients with refractory or relapsed disease will achieve remission, long-term survival rates remain poor, and efforts to identify therapies which will improve OS are under continuous investigation. The current fundamental goal of such investigation is the achievement of as complete a remission as possible without dose-limiting toxicities, and the progression to hematopoietic stem cell transplantation thereafter. In this review the scope of the problem of relapsed and refractory AML as well as current and emerging chemotherapy options will be discussed.",
author = "Davila, {Jennifer G.} and Emily Slotkin and Thomas Renaud",
year = "2014",
doi = "10.1007/s40272-013-0048-y",
language = "English (US)",
volume = "16",
pages = "151--168",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Relapsed and refractory pediatric acute myeloid leukemia

T2 - Current and emerging treatments

AU - Davila, Jennifer G.

AU - Slotkin, Emily

AU - Renaud, Thomas

PY - 2014

Y1 - 2014

N2 - Survival rates for children with acute myeloid leukemia (AML) exceed 60 % when modern, intensified chemotherapeutic regimens and enhanced supportive care measures are employed. Despite well-recognized improvements in outcomes, primary refractory or relapsed pediatric AML yields significant morbidity and mortality, and improved understanding of this obstinate population along with refined treatment protocols are urgently needed. Although a significant number of patients with refractory or relapsed disease will achieve remission, long-term survival rates remain poor, and efforts to identify therapies which will improve OS are under continuous investigation. The current fundamental goal of such investigation is the achievement of as complete a remission as possible without dose-limiting toxicities, and the progression to hematopoietic stem cell transplantation thereafter. In this review the scope of the problem of relapsed and refractory AML as well as current and emerging chemotherapy options will be discussed.

AB - Survival rates for children with acute myeloid leukemia (AML) exceed 60 % when modern, intensified chemotherapeutic regimens and enhanced supportive care measures are employed. Despite well-recognized improvements in outcomes, primary refractory or relapsed pediatric AML yields significant morbidity and mortality, and improved understanding of this obstinate population along with refined treatment protocols are urgently needed. Although a significant number of patients with refractory or relapsed disease will achieve remission, long-term survival rates remain poor, and efforts to identify therapies which will improve OS are under continuous investigation. The current fundamental goal of such investigation is the achievement of as complete a remission as possible without dose-limiting toxicities, and the progression to hematopoietic stem cell transplantation thereafter. In this review the scope of the problem of relapsed and refractory AML as well as current and emerging chemotherapy options will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=84898413310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898413310&partnerID=8YFLogxK

U2 - 10.1007/s40272-013-0048-y

DO - 10.1007/s40272-013-0048-y

M3 - Article

C2 - 24158739

AN - SCOPUS:84898413310

VL - 16

SP - 151

EP - 168

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 2

ER -